POSC162 Cost Effectiveness Analysis of Nivolumab Plus Ipilimumab Therapy in Patients with Advanced Non-Small Cell Lung Cancer in Japan

Autor:	X Mo, K Moriwaki, K Morimoto, K Shimozuma
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S118-S119
ISSN:	1098-3015
DOI:	10.1016/j.jval.2021.11.564
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2519d441e0d7d00afa4936de3557ab10 https://doi.org/10.1016/j.jval.2021.11.564 Zobrazit plný text záznamu Full Text from ScienceDirect